Nasal vs Encapsulated Delivery
Research Comparison

Research Overview

This page compares two administration formats studied for research peptides and small molecules: the intranasal format (a reconstituted aqueous solution delivered by metered spray onto the nasal mucosa) and the encapsulated format (a solid powder or lyophilizate filled into capsules or compressed into tablets, often with an enteric coat). This is a route and dosage-form comparison, not a comparison of two molecules, so classical small-molecule identity fields such as CAS number, molecular formula, and molecular weight do not apply to the page subject itself. The identity numbers cited below belong to representative excipients, not to a single active.

The two formats differ mechanistically at the absorption barrier rather than at a shared molecular target. The intranasal format is studied as a way to deposit a compound on richly vascularized respiratory epithelium so that reported absorption bypasses gastrointestinal proteolysis and hepatic first-pass metabolism, and a distinguishing feature examined preclinically is the nose-to-brain pathway. The encapsulated format is studied as a way to carry a larger absolute mass in a solid dosage form while contending with gastric acid, gastrointestinal and pancreatic proteases, poor epithelial permeability, and first-pass metabolism, typically addressed with enteric coating plus intestinal permeation enhancers.

All statements here describe in-vitro and preclinical research context, plus published human delivery-science literature on the formats themselves. Nothing on this page describes a use, benefit, or outcome for any person. Any specific vialed or encapsulated product's fill mass, concentration, excipient list, and purity must be confirmed against the batch COA.

Reference Data

Identity values are compiled from public chemistry databases and vendor documentation. Confirm the exact salt form, molecular weight, and purity for a given batch against its Certificate of Analysis (COA).

Structure and Class

Neither format is a single chemical, so the reference identity below describes the format class and the representative excipients most often studied in each, not one molecule. The intranasal format is best described as an administration route (intranasal mucosal delivery), and the encapsulated format as a solid oral dosage form (capsule or enteric-coated tablet). The peptide active in both formats typically begins as a lyophilized powder; the nasal format requires reconstitution to an aqueous spray, while the encapsulated format is filled or compressed as a solid.

Representative nasal-format excipients that carry their own confirmed identity include benzalkonium chloride (PubChem CID 3014024), a preservative appearing in some nasal vehicles, and solubilizers such as 2-hydroxypropyl-beta-cyclodextrin (PubChem CID 14049689, molecular formula C63H112O42, molecular weight approximately 1541.5, reported). Cell-penetrating peptides and mucoadhesive polymers are also studied as nasal absorption modifiers.

Representative encapsulated-format excipients are the intestinal permeation enhancers. Salcaprozate sodium, known as SNAC (PubChem CID 23669833, molecular formula C15H20NNaO4, molecular weight approximately 301.31, reported, CAS 203787-91-1), is the enhancer worked out for oral semaglutide. Sodium caprate, the C10 enhancer (PubChem CID 4457968, molecular formula C10H19NaO2, molecular weight approximately 194.25, reported, CAS 1002-62-6), is the other most clinically advanced enhancer. These two have been studied head-to-head for over thirty years (Twarog 2019, PMID 30781867).

Research Context

Intranasal research context. The intranasal format deposits a compound on nasal respiratory and olfactory mucosa, from which reported absorption crosses richly vascularized epithelium and bypasses gastrointestinal proteolysis and hepatic first-pass metabolism. The most distinctive feature studied preclinically is the nose-to-brain (NBDD) pathway: research indicates direct transport toward the central nervous system along olfactory and trigeminal nerve routes plus a respiratory pathway, reportedly bypassing the blood-brain barrier via bulk flow and diffusion in perineuronal, perivascular, and lymphatic channels, with some tracers reaching brain tissue within roughly ten minutes in animal models (Qiu 2025, PMID 40487748). A worked preclinical example is intranasal GDNF and plasmid-DNA nanoparticle gene delivery in a rat Parkinson model as a non-surgical alternative to intracerebral infusion (Aly 2015, PMID 26289676).

The dominant limiters reported for nasal peptide absorption are mucociliary clearance (the mucus layer is reported to renew roughly every ten to twenty minutes, sweeping unabsorbed material to the nasopharynx where it is swallowed), enzymatic degradation in nasal mucosa, and a molecular-size cutoff. Peptides under about 1000 Da are reported to absorb reasonably, 1000 to 6000 Da increasingly poorly, and most marketed intranasal peptide formulations show reported human bioavailability under about 5 percent. The nasal format is also volume-limited, with metered spray typically delivering about 50 to 140 microliters per actuation (roughly 100 microliters per nostril as an often-cited optimum), so only relatively potent, low-mass payloads fit.

Encapsulated research context. The encapsulated format must survive gastric acid and stomach, intestinal, and pancreatic proteases, then cross the intestinal epithelium (large hydrophilic peptides diffuse poorly), then survive hepatic first-pass metabolism, so naked oral peptide bioavailability is characteristically very low. Research formats address this with enteric coating to shield against acid and pepsin and with intestinal permeation enhancers. The canonical enhancer mechanism, worked out for oral semaglutide, is SNAC: it is reported to buffer the local microenvironment, raising pH to roughly 5 or above which inactivates pepsin, to reduce peptide oligomerization in favor of the absorbable monomer, and to transiently and reversibly fluidize the epithelial lipid membrane to boost transcellular passage. Sodium caprate (C10) is reported to work more by transient tight-junction opening plus membrane perturbation (Twarog 2019, PMID 30781867).

The encapsulated permeation-enhancer route is the format with the strongest human validation: it is the delivery basis of oral semaglutide, evaluated in large Phase 3 human trials such as NCT04707469 (oral semaglutide 25 or 50 mg versus 14 mg in type 2 diabetes). That program serves as a research proof-of-concept that a permeation-enhancer capsule can make a peptide orally absorbable. Both SNAC and C10 are reported to produce single-digit, highly variable increases in oral bioavailability in human trials per the Twarog review. By contrast, nasal CNS peptide delivery is largely preclinical to early clinical.

Which Should a Study Use?

Neither format is superior in the abstract; the appropriate choice is driven by the payload and the research question. A study of a small, potent peptide, or one investigating central nervous system exposure via nose-to-brain routes, aligns with the intranasal format, accepting its volume ceiling, mucociliary clearance losses, and the reconstitution and aqueous-stability burden. A study of a larger-mass payload, or one prioritizing a solid dosage form with an established human proof-of-concept for oral macromolecule absorption, aligns with the encapsulated permeation-enhancer format, accepting the acid, protease, and first-pass gauntlet and its typically single-digit, variable absorbed fraction.

Molecular size is often the deciding variable. Where the payload sits relative to the reported nasal thresholds (about 1000 Da reasonable, 1000 to 6000 Da harder) depends on the exact sequence and should be confirmed against the batch COA. Whether any specific compound actually crosses the nose-to-brain barrier at a meaningful level is molecule-dependent and is not established for arbitrary peptides; the cited nose-to-brain evidence is preclinical and tracer-based. Absolute human bioavailability by either route is molecule-specific and is not defined by this page.

Practical handling differs sharply between the formats and should factor into study design. The nasal format introduces daily reconstitution and an aqueous-aggregation risk; the encapsulated format avoids those but is sensitive to moisture, heat, and any damage to the enteric or enhancer matrix. See the handling section below and confirm every product-specific value against the batch COA.

Handling Considerations by Format

Shared starting material. Research peptides typically ship as a lyophilized powder, and unreconstituted lyophilized peptide is reported stable for roughly 24 months or more at -20 C. Exact stability, fill mass, and purity for any given vial or capsule must be confirmed against the batch COA.

Nasal format (requires reconstitution). Add diluent (bacteriostatic or sterile water) slowly down the inside vial wall, never directly onto the powder cake, and never inject with force, because shear promotes aggregation. Do not vortex or shake vigorously, since foaming at the air-liquid interface is reported to drive denaturation and irreversible aggregation; improper technique is reported to reduce effective concentration by roughly 20 to 30 percent. The reconstituted solution is the least stable state: reported potency loss is roughly 5 to 8 percent after 2 to 3 hours at 20 to 25 C and roughly 20 to 30 percent after 24 hours at room temperature. General research handling guidance cited is to use within about 30 days if reconstituted with bacteriostatic water or about 7 days with sterile water only, kept refrigerated. Nasal-specific loss factors to control at use are the metered spray volume (about 50 to 140 microliters per actuation, about 100 microliters per nostril target) and mucociliary clearance (about 10 to 20 minute mucus turnover), noting the reported trade-off that anterior deposition gives longer residence but lower permeability while posterior gives higher permeability but faster clearance.

Encapsulated format (solid, generally no reconstitution). The main handling risks are moisture and heat, so keep capsules and tablets dry, cool, and sealed with desiccant. Enteric coats are designed to hold in gastric pH and dissolve in the intestine, so anything that degrades the coat (humidity, mechanical damage) can expose the peptide to gastric proteolysis. Permeation-enhancer tablets depend on a high local enhancer concentration at the mucosa, so splitting or crushing an enteric or enhancer-matrix tablet can defeat both protection and absorption. All specific storage temperatures, in-use dating, diluent choice, excipient lists, and purity are product-specific and must be confirmed against the batch COA. For general lyophilized handling and reconstitution math, see the Lyophilized Storage Guide and the Reconstitution Calculator.